Activity Overview
This educational activity is an archive of the live presentation held on May 29, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists,
thoracic surgeons, pulmonologists, radiation oncologists, pathologists, nurse
practitioners, physician assistants, pharmacists, oncology nurses, and other
health care providers who manage patients with early-stage non-small cell lung
cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate contemporary clinical trial evidence supporting immunotherapy across stages I-III NSCLC
- Incorporate multidisciplinary assessment and molecular/biologic features into evidence-based, individualized treatment decisions for patients with resectable and unresectable early-stage NSCLC
- Apply best practices for mitigating and managing immune-related adverse effects in patients with early-stage NSCLC
Tina Cascone, MD, PhD
Associate Professor
Physician-Scientist
Director of Translational Research
Department of Thoracic/Head and Neck
Medical Oncology
The University of Texas MD Anderson
Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Daiichi Sankyo, Genentech, IDEOlogy Health, Merck, Nuvalent, oNKo-innate, Pfizer, RAPT Therapeutics, Summit Therapeutics; Institutional Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Merck
Puneeth Iyengar, MD, PhD
Radiation Oncologist
Director, Metastatic Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Johnson & Johnson, Novocure, Pfizer; Grant/ Research Funding: Incyte
Paula A. Ugalde Figueroa, MD
Associate Professor of Surgery
Co-director, Continuing Medical Education
Harvard Medical School
Associate Thoracic Surgeon
Canepari Family Endowed Chair in Thoracic Surgery
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Medtronic/Covidien
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
